BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ISH0688 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ISH0688\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07505043-1211@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ISH0688: Phase 1 readout est. (NCT07505043)
DESCRIPTION:ISH0688\, phase 1\, Hypertriglyceridemia.\nStudy: First-in-Huma
 n Study of ISH0688: Safety\, Tolerability\, Pharmacokinetics\, and Pharmac
 odynamics\nEstimated primary completion: 28 February 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ish0688#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07505043
URL:https://assetmemo.bio/drug/ish0688#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
